Skip to content

Intravenous (IV) Nitroglycerin for Versions in Multiparous Women

Intravenous (IV) Nitroglycerin for Versions in Multiparous Women

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00901758
Acronym
INVERT (02)
Enrollment
44
Registered
2009-05-14
Start date
2003-03-31
Completion date
2008-02-29
Last updated
2013-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breech Presentation, Pregnancy Complication

Brief summary

Breech presentations (where a baby presents with feet or bottom down) have an increased risk of perinatal and neonatal complications, and are usually delivered by cesarean section. As an alternative, so that the baby can be delivered vaginally, an attempt can be made to turn the baby so that it is head down: this manoeuvre is called an external cephalic version (ECV). Drugs that relax the uterus (tocolytic agents) are sometimes used to help improve ECV success rates. Nitroglycerin is a tocolytic agent, but intravenous nitroglycerin has not been tested as an agent to help ECV. There is some suggestion that nitroglycerin may be more helpful in women who have not previously been pregnant (nulliparous women) than in women who have been pregnant more than once (multiparous women), and so we have planned two trials. This study is designed to answer the following questions for multiparous women: Will administration of IV nitroglycerin for uterine relaxation improve ECV success rates? Will an increase in ECV success result in a decreased cesarean section rate?

Interventions

IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL.

DRUGNormal saline

IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL

Sponsors

University of Calgary
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* any non-cephalic presentation * singleton pregnancy * \>/= 37 weeks gestational age * normal amniotic fluid volume * reassuring fetal heart rate

Exclusion criteria

* labor * ruptured membranes * history of third trimester bleeding * any pre-existing uterine scar * pregnancy induced hypertension and gestational diabetes * oligohydramnios and polyhydramnios * intrauterine growth restriction or macrosomia * hypotension or any serious medical illness * inability to comprehend consent form

Design outcomes

Primary

MeasureTime frame
Success of ECV (if fetus turned from Breech to cephalic) at end of ECV procedureRecorded at the end of ECV attempt

Secondary

MeasureTime frame
Success of ECV (ie fetus in cephalic presentation) recorded at time of deliveryRecorded at time of birth
Mode of deliveryRecorded at time of birth
Maternal side effects and adverse eventsRecorded until date of birth (up to 3 weeks' duration).

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026